To include your compound in the COVID-19 Resource Center, submit it here.
Repros began the fourth cohort of 9 mg oral Proellex in a U.S. Phase II trial after a safety
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury